Clinical Trial Update: Assessment of the Role of Tegaserod Therapy in the Management of Gastroesophageal Reflux Disease (GERD) Symptoms in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs). [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update evaluating tegaserod for GERD symptoms in patients with incomplete response to PPIs has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroesophageal Reflux Disease

Drugs mentioned

• Tegaserod (tegaserod)

Snippet

Sponsor: Novartis | Conditions: Gastroesophageal Reflux Disease (GERD) | Phase 3 | Status: COMPLETED